HONG KONG – Pharmcadd Co. Ltd., a developer of an artificial intelligence (AI) and physics-based drug discovery platform, bagged ₩17.3 billion (US$15.5 million) in its series B funding. This brings the total funds raised since its establishment to $22 million.
HONG KONG – Pharmcadd Co. Ltd., a developer of an artificial intelligence (AI) and physics-based drug discovery platform, bagged ₩17.3 billion (US$15.5 million) in its series B funding. This brings the total funds raised since its establishment to $22 million.
With the prevalence of central nervous system disorders such as Alzheimer’s disease, multiple sclerosis, epilepsy, Parkinson’s disease and stroke increasing annually, the need for novel therapeutics to treat neurologic and psychiatric disorders has never been greater. Unfortunately, even though there is a significant unmet medical need, because of the high risk and low approval rates of drugs targeting those devastating diseases, in the past decade big pharma companies have been dramatically reducing their R&D spending on CNS disorders, noted Naheed Kurji, president and CEO of Toronto-based Cyclica Inc.
LONDON – Artificial intelligence (AI) drug design specialist Exscientia Ltd. has completed a sizable extension to its series C, adding a further $40 million to the $60 million raised in May 2020.
HONG KONG – Hummingbird Bioscience Pte. Ltd. is collaborating with artificial intelligence (AI) company Tempus Labs Inc. to advance HMBD-001, a differentiated anti-HER3 neutralizing antibody developed using Hummingbird's Rational Antibody Discovery platform, into clinical trials in HER3-driven cancers.
Genesis Therapeutics Inc. CEO and co-founder Evan Feinberg likens the collaboration of his company’s team of chemists, biologists and software developers to that of a jazz band. Everyone has to be familiar with everyone else’s roles and responsibilities in order to do their job, or play a solo, when it’s their turn.
Castle Biosciences Inc.'s Decisiondx Diffdx-Melanoma test is now commercially available to help dermatopathologists better characterize melanocytic lesions. About 15% of suspicious pigmented skin lesions cannot be definitively determined to be benign or malignant using common methods. The new gene expression profile test reduces the number of indeterminate results by more than 70%.
LONDON – COVID-19 research is generating a wealth of data every day, but it is coming from many and disparate sources, making it difficult to assess its quality, dovetail datasets together and decide how to apply it.
LONDON – COVID-19 research is generating a wealth of data every day, but it is coming from many and disparate sources, making it difficult to assess its quality, dovetail datasets together and decide how to apply it.
Privately held Dyno Therapeutics Inc., an early stage biotech company applying artificial intelligence to gene therapy, entered a collaboration and license agreement with Spark Therapeutics Inc. that could bring Dyno milestone payments exceeding $1.8 billion.
